DANVILLE, Pa. – Geisinger has begun using a new patient management system to expand its ability to identify and manage patients with incidentally identified lung abnormalities, as well as manage those eligible for lung cancer screening.
Nationally, incidental abnormalities are found about 40% of the time during imaging tests that are unrelated to the reason the test was ordered. In 2020, Geisinger implemented the STAIR™ Program (which stands for System to Track Abnormalities of Importance Reliably) to help manage these patients. If an incidental lung abnormality is found, the provider refers the patient to the STAIR team, which evaluates the patient and establishes a care plan.